KSHV

From WikiMD's WELLNESSPEDIA

Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), is a type of human herpesvirus. It is known to cause several types of cancer, including Kaposi's sarcoma, primary effusion lymphoma, and some types of multicentric Castleman's disease.

Discovery[edit]

KSHV was first identified in 1994 in Kaposi's sarcoma lesions of AIDS patients by Chang, Moore and colleagues. The discovery was made possible by the development of representational difference analysis, a technique used to subtract the genetic material of healthy cells from the genetic material of tumor cells.

Transmission[edit]

KSHV is not highly contagious, but it can be transmitted. The virus is believed to be transmitted through saliva. It can also be transmitted through organ transplantation and blood transfusion.

Diseases[edit]

KSHV is known to cause several types of cancer, including:

  • Kaposi's sarcoma: A type of cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs.
  • Primary effusion lymphoma: A rare type of non-Hodgkin lymphoma that affects body cavities like the space around the lungs or the abdomen.
  • Multicentric Castleman's disease: A rare lymphoproliferative disorder characterized by fever, weight loss, anemia, and night sweats.

Prevention and Treatment[edit]

There is currently no vaccine available to prevent KSHV infection. Treatment for diseases caused by KSHV includes antiviral therapy, chemotherapy, and immunotherapy.

See Also[edit]

References[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.